OakChart

Mineralys Therapeutics Inc

MLYSHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:46 PM ET

16.28+0.76 (4.90%)
2026-11-11 21:47 CET
Market cap
1,374.41 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-369.97 USD m
Free cash flow, TTM
-153.03 USD m
EPS diluted, TTM
-4.36
P/E
-
Compare

Price

MLYS against its 20, 50 and 200-day averages
2050200miss
15.0020.0025.0030.004.1M8.2MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26MLYSclose 16.2820-day 18.8450-day 23.19200-day 26.3216.2852w low

65.8% under the 52-week high of 47.65 on 12 Nov 2025. 52-week low 14.91 on 6 Nov 2026. Last 15 sessions, 50.8% high to low

Volume 0.93× normal · the line is the 50-bar volume average

Profile

MLYS
52-week range, 4% of the way up
14.9147.65

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

IndexRUT
Employees76
IPOFeb 10, 2023
Beta0.89
ATR, 14d1.43
Rel volume0.93
Short float12.61%
Insider own31.19%
Inst own87.91%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.44B
Enterprise Value915.31M
Income-369.97M
Sales0.00M
Book/sh5.69
Cash/sh7.05
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees76
IPOFeb 10, 2023

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B2.86
P/C2.31
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio11.83
Current Ratio11.83
Debt/Eq0.20
LT Debt/Eq0.15
Option/ShortYes / Yes

Earnings

EPS (ttm)-4.36
EPS next Y-2.47
EPS next Q-0.69
EPS this Y-102.84%
EPS next Y46.80%
EPS next 5Y11.38%
EPS past 3/5Y-46.34% -101.68%
Sales past 3/5Y- -
EPS Y/Y TTM-47.55%
Sales Y/Y TTM-
EPS Q/Q-23.13%
Sales Q/Q-
EarningsNov 04 AMC
EPS/Sales Surpr.-15.36% -

Ownership

Insider Own31.19%
Insider Trans-1.67%
Inst Own87.91%
Inst Trans10.09%
ROA-60.15%
ROE-68.50%
ROIC-64.11%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-13.58%
SMA50-29.80%
SMA200-38.16%
Trades-

Technical

Shs Outstand88.53M
Shs Float60.94M
Short Float12.61%
Short Ratio5.23
Short Interest7.69M
52W High47.65 -65.83%
52W Low14.91 9.19%
Volatility9.75% 7.90%
ATR (14)1.43
RSI (14)35.30
Beta0.89
Rel Volume0.93
Avg Volume1.47M
Volume1,323,516

Performance

Perf Week-4.24%
Perf Month-22.48%
Perf Quarter-37.60%
Perf Half Y-39.39%
Perf YTD-55.14%
Perf Year-65.44%
Perf 3Y152.40%
Perf 5Y-
Perf 10Y-
Recom1.40
Target Price43.56
Prev Close15.52
Price16.28
Change %4.90%

Analyst ratings

latest 10 of 11
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSNeutral$29+78.1%
Apr 27, 2026InitiatedTTD CowenBuy
Jun 11, 2025InitiatedJJefferiesHold$15-7.9%
Jul 10, 2024InitiatedHH.C. WainwrightBuy$30+84.3%
Apr 02, 2024InitiatedGGoldmanBuy$30+84.3%
Mar 07, 2023InitiatedWWells FargoOverweight$27+65.8%
Mar 07, 2023InitiatedSStifelBuy$45+176.4%
Mar 07, 2023InitiatedGGuggenheimBuy$32+96.6%
Mar 07, 2023InitiatedEEvercore ISIOutperform
Mar 07, 2023InitiatedCCredit SuisseOutperform$40+145.7%

Peers

Mkt cap
TickerCompanyMkt cap
NAMSNewAmsterdam Pharma Company NV2.48B
ALNYAlnylam Pharmaceuticals Inc21.21B
AZNAstrazeneca plc287.60B
MAZEMaze Therapeutics Inc2.01B
VERAVera Therapeutics Inc2.19B
ARDXArdelyx Inc785.54M
CYTKCytokinetics Inc8.17B
ARWRArrowhead Pharmaceuticals Inc6.96B
MISTMilestone Pharmaceuticals Inc84.15M
AKBAAkebia Therapeutics Inc157.33M

Insider trading

latest 14 of 100
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Rodman David MalcomOfficerOct 13 '26Proposed Sale22.043,54278,066Oct 13 04:11 PM
Congleton JonChief Executive OfficerSep 30 '26Sale25.4675,0001,909,665528,621Oct 02 05:53 PM
Congleton JonOfficerSep 30 '26Proposed Sale25.4675,0001,909,662Sep 30 04:07 PM
Slingsby Brian TaylorDirectorSep 22 '26Sale28.81104,3203,005,3037,805,718Sep 24 09:49 PM
Warren EricChief Commercial OfficerSep 21 '26Option Exercise13.247,43898,47945,838Sep 22 06:48 PM
Warren EricChief Commercial OfficerSep 21 '26Sale28.127,438209,13638,400Sep 22 06:48 PM
CATALYS PACIFIC FUND LPDirectorSep 22 '26Proposed Sale28.81104,3203,005,303Sep 22 04:09 PM
Warren EricOfficerSep 21 '26Proposed Sale28.127,438209,135Sep 21 04:05 PM
Karydas DaphneDirectorSep 15 '26Option Exercise12.023,00036,0609,200Sep 17 05:41 PM
Karydas DaphneDirectorSep 15 '26Sale28.583,00085,7406,200Sep 17 05:41 PM
Rodman David MalcomOfficerSep 17 '26Proposed Sale27.9541711,655Sep 17 04:06 PM
Karydas DaphneOfficerSep 15 '26Proposed Sale28.583,00085,740Sep 15 04:19 PM
Rodman David MalcomOfficerSep 14 '26Proposed Sale28.147,709216,931Sep 14 04:06 PM
Rodman David MalcomOfficerSep 09 '26Proposed Sale30.872,17167,019Sep 09 04:05 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VHTVanguard Health Care ETFAUM: 21.51B

News

latest 14 of 200
  • Mineralys stock gains after drug shows sustained blood pressure cuts (Investing.com)
  • Mineralys Therapeutics Presents New Late-Breaking Data from Transform-HTN Open-Label Extension Trial of Lorundrostat in Hypertension at AHA Scientific Sessions 2026 (GlobeNewswire)
  • Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • Mineralys Misses As Launch Spending Surges; Lorundrostat Readiness Improves While The Stock Slides To A 52-Week Low (Earnings Whispers) +6.32% -10.35%
  • Mineralys Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • Mineralys Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • Mineralys Heads Into Final Pre-PDUFA Report With Launch Readiness And Cash Burn In Focus (Earnings Whispers)
  • Mineralys Therapeutics to Announce Third Quarter 2026 Financial Results and Host Conference Call on Wednesday, November 4, 2026 (GlobeNewswire)
  • Mineralys Therapeutics Announces Publication of Phase 2 Explore-CKD Trial Results for Lorundrostat in Kidney International (GlobeNewswire)
  • Mineralys Therapeutics Presents New Lorundrostat Data in Participants with Hypertension and Chronic Kidney Disease at ASN Kidney Week 2026 (GlobeNewswire)
  • Mineralys Therapeutics Expands its Board of Directors with the Appointments of Kristine Peterson and Lonnel Coats (GlobeNewswire)
  • Mineralys Therapeutics Presents New Data for Lorundrostat at the American Heart Association Hypertension Scientific Sessions 2026 (GlobeNewswire)
  • Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026 (GlobeNewswire)
  • Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026 (GlobeNewswire) -5.61%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.640-0.555-0.6410.000.008
2026Q22026-08-11-2.850-0.549-2.8450.000.007
2026Q12026-05-06-0.470-0.472-0.4750.000.007
2025Q42026-03-12-0.400-0.516-0.4000.000.008
2025Q32025-11-10-0.520-0.613-0.5230.000.007
2025Q22025-08-12-0.660-0.739-0.6610.000.007
2025Q12025-05-12-0.790-0.982-0.7940.000.005
2024Q42025-02-12-0.980-1.077-0.9800.000.007
2024Q32024-11-11-1.130-0.863-1.1310.000.006
2024Q22024-08-13-0.830-0.700-0.8310.000.007
2024Q12024-05-09-0.700-0.668-0.7020.000.005
2023Q42024-03-21-0.610-0.825-0.6080.000.004
2023Q32023-11-07-0.570-0.760-0.5540.000.004
2023Q22023-08-07-0.310-0.720-0.2970.000.004
2023Q12023-05-15-0.510-0.890-0.3090.000.004
2022Q42023-03-15-1.740-1.716-0.2220.000.001

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-5.770-4.446-0.7290.000.00
2023FY-1.990-2.278-1.9870.000.00
2024FY-3.660-3.713-3.6630.000.00
2025FY-2.290-2.386-2.2900.000.00
2026FY--4.645--0.00
2027FY--2.471--75.24
2028FY--1.594--228.99
2029FY-0.894--569.38
2030FY-3.752--993.63

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-058000.000.000.00
2026Q4S2026-11-048000.000.000.00
2026Q4S2026-10-098000.000.000.00
2026Q4S2026-08-127000.000.000.00
2026Q4S2026-05-077000.000.000.00
2026Q4S2026-04-246000.000.000.00
2026Q4S2026-03-135000.000.000.00
2026Q4S2025-12-184000.000.000.00
2026Q4S2025-11-113000.000.000.00
2026Q4S2025-11-101000.000.000.00
2026Q4S2025-11-091000.000.000.00
2026Q4S2025-11-081000.000.000.00
2026Q4S2025-11-071000.000.000.00
2026Q4S2025-11-061000.000.000.00

Estimate history

EPS, annual-0.069-0.361-0.729-1.987-3.663-2.286-4.3646
Period202020212022202320242025TTM
EPS, quarterly-1.131-0.98-0.794-0.661-0.523-0.4-0.475-2.845-0.644
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual0000000
Period202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual58.43858.76340.85741.13449.82281.53788.53
Period202020212022202320242025MRQ
Shares, quarterly49.75649.82264.87665.72578.96981.53782.45588.35188.53
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.030.060.040.000.000.000.00
Gross Profit-0.03-0.06-0.040.000.000.000.00
Selling, General and Administrative Excl. Other389.72170.54192.3684.6631.4818.732.94
Research and Development292.81132.01168.5870.3626.2516.312.41
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-389.75-170.60-192.40-84.66-31.48-18.73-2.94
Interest Expense-0.000.000.000.000.030.12
Unusual Expense0.000.000.000.000.000.660.37
Net Income Before Taxes-369.97-154.65-177.81-71.90-29.80-19.41-3.43
Income Taxes0.000.000.000.000.000.000.00
Consolidated Net Income-369.97-154.65-177.81-71.90-29.80-19.41-3.43
Net Income From Continuing Operations-369.97-154.65-177.81-71.90-29.80-19.41-3.43
Net Income-369.97-154.65-177.81-71.90-29.80-19.41-3.43
EPS (Recurring)-4.16-2.29-3.66-1.99-0.73-0.35-0.06
EPS (Basic, Before Extraordinaries)-4.36-2.29-3.66-1.99-0.73-0.36-0.07
EPS (Diluted)-4.36-2.29-3.66-1.99-0.73-0.36-0.07
EBITDA-389.72-170.54-192.36-84.66-31.48-18.73-2.94
Non-Operating Income (Expense)22.9615.9514.5912.761.680.00-0.00
Other After Tax Adjustments0.000.000.000.000.000.000.00
Stock Option Compensation Expense27.0719.3211.345.060.460.080.00
Shares Outstanding88.5381.5449.8241.1340.8658.7658.44
Market Capitalization1,374.411,374.41612.65353.50353.50--

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.010.010.010.010.010.020.010.01
Gross Profit-0.01-0.01-0.01-0.01-0.01-0.02-0.01-0.01
Selling, General and Administrative Excl. Other60.08246.0345.3338.2741.1246.7344.4351.75
Research and Development22.67221.3824.3624.4031.4538.2837.8844.57
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-60.09-246.04-45.34-38.28-41.13-46.75-44.45-51.77
Interest Expense3.19-0.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes-57.33-241.07-39.34-32.23-36.93-43.27-42.21-48.95
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-57.33-241.07-39.34-32.23-36.93-43.27-42.21-48.95
Net Income From Continuing Operations-57.33-241.07-39.34-32.23-36.93-43.27-42.21-48.95
Net Income-57.33-241.07-39.34-32.23-36.93-43.27-42.21-48.95
EPS (Recurring)-0.64-2.85-0.47-0.40-0.52-0.66-0.79-0.98
EPS (Basic, Before Extraordinaries)-0.64-2.85-0.47-0.40-0.52-0.66-0.79-0.98
EPS (Diluted)-0.64-2.85-0.47-0.40-0.52-0.66-0.79-0.98
EBITDA-60.08-246.03-45.33-38.27-41.12-46.73-44.43-51.75
Non-Operating Income (Expense)5.954.976.006.054.203.472.242.82
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.887.366.555.295.843.602.883.13
Shares Outstanding88.5388.3582.4581.5478.9765.7364.8849.82
Market Capitalization1,374.412,378.522,232.202,871.992,941.44881.82997.02612.65

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments656.63198.19236.57110.1110.661.41
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.757.1612.542.700.460.06
Total Current Assets661.39205.35249.10112.8111.121.47
Net Property, Plant & Equipment0.040.050.000.000.000.00
Total Investments and Advances0.000.002.480.000.000.00
Intangible Assets---0.000.000.00
Other Assets0.380.500.051.630.000.02
Total Assets661.81205.90251.64114.4411.121.49
Short Term Debt Incl. Current Port. of LT Debt0.000.000.000.000.004.50
Accounts Payable2.020.480.601.910.000.00
Other Current Liabilities13.1014.179.886.165.050.58
Total Current Liabilities15.1114.6510.488.075.055.08
Long Term Debt0.000.000.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities15.1114.6510.488.075.055.08
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.00158.6429.000.00
Common Equity646.69191.26241.15-52.27-22.93-3.60
Total Shareholders Equity646.69191.26241.15106.386.07-3.60
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity646.69191.26241.15106.386.07-3.60
Total Liabilities & Stockholders Equity661.81205.90251.64114.4411.121.49
Book Value Per Share7.933.845.86-1.28-0.39-0.06
Tangible Book Value Per Share7.933.845.86-1.28-0.39-0.06
Full-Time Employees76512812--
Price to Book Ratio2.732.591.341.34--
Return on Assets-35.65-77.72-39.28-47.46-307.79-
Return on Equity-36.91-82.24-41.38-53.00-1,568.96-
Return on Invested Capital-23.91-92.97-29.81-28.01-319.68-
Quick Ratio43.7614.0223.7613.982.200.29
Current Ratio43.7614.0223.7613.982.200.29

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-369.97-154.65-177.81-71.90-29.80-19.41-3.43
Depreciation0.030.060.04----
Other Funds (Non Cash)209.579.451.93-1.80-0.190.760.48
Funds from Operations-160.37-145.15-175.84-73.70-29.99-18.64-2.94
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital7.362.739.52-7.470.774.080.48
Cash from Operating Activities-153.01-142.42-166.31-81.17-29.22-14.56-2.46
Capital Expenditures-0.01-0.01-0.100.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.00
Purchase or Sale of Investments-128.90-389.74115.06-160.47-21.760.000.00
Purchase of Investments-1,213.90-814.74-373.44-347.97-71.760.000.00
Sale Or Maturity of Investments1,085.00425.00488.50187.5050.000.000.00
Other Uses-200.040.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-328.95-389.75114.96-160.47-21.760.000.00
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock269.77591.00116.14203.25128.0223.81-0.02
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock269.77591.00116.14203.25128.0223.81-0.02
Proceedsfrom Stock Options255.82578.21115.84203.05128.0223.81-0.02
Issuance or Reduction of Debt, Net95.860.000.000.000.000.003.85
Change in Long Term Debt95.860.000.000.000.000.000.00
Issuance of Long Term Debt95.860.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.00
Cash from Financing Activities365.64591.00116.14203.25128.0223.813.83
Net Change in Cash-116.3258.8364.79-38.4077.049.251.37
Free Cash Flow-153.03-142.43-166.41-81.17-29.22-14.56-2.46
Preferred Dividends (Cash Flow)-0.000.000.000.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments624.67661.41646.06656.63593.63324.92
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets3.324.396.414.756.1710.35
Total Current Assets627.99665.80652.47661.39599.80335.27
Net Property, Plant & Equipment0.020.030.030.040.010.02
Total Investments and Advances0.000.000.000.000.000.00
Other Assets2.112.020.360.380.140.43
Total Assets630.12667.85652.86661.81599.95335.72
Short Term Debt Incl. Current Port. of LT Debt25.000.000.000.000.000.00
Accounts Payable0.741.071.122.021.123.16
Other Current Liabilities27.3418.2513.6013.1022.4019.01
Total Current Liabilities53.0819.3214.7215.1123.5222.17
Long Term Debt73.2797.620.000.000.000.00
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.000.00
Total Liabilities126.35116.9414.7215.1123.5222.17
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity503.77550.92638.14646.69576.43313.55
Total Shareholders Equity503.77550.92638.14646.69576.43313.55
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity503.77550.92638.14646.69576.43313.55
Total Liabilities & Stockholders Equity630.12667.85652.86661.81599.95335.72
Book Value Per Share5.696.247.747.937.304.77
Tangible Book Value Per Share5.696.247.747.937.304.77
Full-Time Employees---76--
Price to Book Ratio2.733.493.424.977.952.57
Return on Assets-60.15-69.67-30.12-35.65-39.48-58.32
Return on Equity-68.50-80.88-30.98-36.91-42.14-63.21
Return on Invested Capital-9.93-37.17-6.16-4.98-6.41-13.80
Quick Ratio11.8334.4644.3343.7625.5015.12
Current Ratio11.8334.4644.3343.7625.5015.12

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-57.33-241.07-39.34-32.23-36.93-43.27
Depreciation0.010.010.010.010.010.02
Other Funds (Non Cash)3.73202.841.921.083.442.32
Funds from Operations-53.59-38.23-37.41-31.14-33.47-40.93
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital10.495.67-2.06-6.744.6010.77
Cash from Operating Activities-43.10-32.56-39.47-37.89-28.87-30.17
Capital Expenditures0.000.000.00-0.010.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments4.7414.78-44.94-103.47-150.51-42.88
Purchase of Investments-287.76-310.22-347.44-268.47-300.51-117.88
Sale Or Maturity of Investments292.50325.00302.50165.00150.0075.00
Other Uses-0.04-200.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities4.70-185.22-44.94-103.49-150.51-42.88
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock2.02146.7824.2796.70295.199.83
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock2.02146.7824.2796.70295.199.83
Proceedsfrom Stock Options-0.31144.1720.2291.74288.568.75
Issuance or Reduction of Debt, Net-0.6296.490.000.000.000.00
Change in Long Term Debt-0.6296.490.000.000.000.00
Issuance of Long Term Debt-0.6296.490.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.40243.2624.2796.70295.199.83
Net Change in Cash-36.9925.49-60.14-44.68115.81-63.22
Free Cash Flow-43.10-32.56-39.47-37.90-28.87-30.17

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.61%7.7M60.9M1.27M
2026-10-1512.23%7.4M60.8M1.10M
2026-09-3012.83%7.8M60.8M1.03M
2026-09-1515.14%9.2M60.6M1.12M
2026-08-3115.39%9.3M60.6M1.30M
2026-08-1416.10%9.6M59.9M1.39M
2026-07-3113.67%9.3M68.1M1.45M
2026-07-1514.71%9.6M64.9M1.51M
2026-06-3017.10%11.1M64.9M1.59M
2026-06-1513.42%8.7M64.8M1.47M
2026-05-2915.62%9.5M60.7M1.27M
2026-05-1514.88%9.0M60.7M1.20M
2026-04-3013.90%8.5M61.4M1.23M
2026-04-1514.32%8.8M61.3M1.25M
2026-03-3113.63%8.4M61.4M1.25M
2026-03-1314.57%8.9M61.4M1.26M
2026-02-2716.29%9.6M59.0M1.27M
2026-02-1316.92%10.0M59.0M1.45M
2026-01-3017.91%10.1M56.4M1.52M
2026-01-1518.26%10.3M56.4M1.49M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.5011.5016.100.0025.8350.000.000.993-0.0180.001
call5.009.0013.500.0012.3300.000.000.988-0.0180.001
call7.506.5011.300.008.8970.000.000.894-0.2040.005
call10.004.008.300.005.7990.000.000.840-0.1950.006
call12.501.506.100.004.3870.000.000.769-0.1730.008
call15.000.502.901.382.2842500.000.657-0.1350.009
call17.500.201.500.051.9403011.000.489-0.1280.010
call20.000.052.050.302.6945.000.000.389-0.1480.010
call22.500.051.750.053.45542.000.000.376-0.1890.010
call25.000.001.000.103.1214040.000.262-0.1460.008
call30.000.000.950.053.7269220.000.224-0.1600.008
call35.000.050.700.054.05326.000.000.171-0.1390.006
call40.000.003.100.054.3659.000.000.160-0.1490.006
put2.500.000.050.005.6810.000.00-0.008-0.0150.001
put5.000.000.050.003.5720.000.00-0.013-0.0150.001
put7.500.003.200.005.0060.000.00-0.091-0.1120.004
put10.000.003.100.003.4700.000.00-0.134-0.1030.005
put12.500.002.050.003.9640.000.00-0.231-0.1720.008
put15.000.351.900.992.5791,8010.00-0.343-0.1330.009
put17.500.504.602.103.8342010.00-0.516-0.1240.010
put20.002.106.004.503.54937.000.00-0.609-0.1450.010
put22.505.408.406.853.9592060.00-0.651-0.1700.009
put25.006.6011.007.004.6043.000.00-0.676-0.1870.009
put30.0011.6016.000.005.3360.000.00-0.776-0.1570.008
put35.0016.4021.000.005.8600.000.00-0.830-0.1380.006
put40.0021.3026.000.006.3390.000.00-0.840-0.1460.006

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-10-29SEC
2026-10-298-KCurrent report2026-10-27SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-203Initial statement of beneficial ownership of securities2026-10-19SEC
2026-10-204Statement of changes in beneficial ownership of securities2026-10-19SEC
2026-10-203Initial statement of beneficial ownership of securities2026-10-19SEC
2026-10-198-KCurrent report2026-10-16SEC
2026-10-13144Filing for proposed sale of securities under Rule 144.SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-244Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-09-22144Filing for proposed sale of securities under Rule 144.SEC
2026-09-224Statement of changes in beneficial ownership of securities2026-09-21SEC
2026-09-21144Filing for proposed sale of securities under Rule 144.SEC
2026-09-17144Filing for proposed sale of securities under Rule 144.SEC
2026-09-174Statement of changes in beneficial ownership of securities2026-09-15SEC
2026-09-15144Filing for proposed sale of securities under Rule 144.SEC
2026-09-14144Filing for proposed sale of securities under Rule 144.SEC
2026-09-09144Filing for proposed sale of securities under Rule 144.SEC
2026-08-254Statement of changes in beneficial ownership of securities2026-08-21SEC
2026-08-21144Filing for proposed sale of securities under Rule 144.SEC
2026-08-17144Filing for proposed sale of securities under Rule 144.SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-123Initial statement of beneficial ownership of securities2026-08-10SEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-1110-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-118-KCurrent report2026-08-05SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-09005.21M4
2026-0800251.97K2
2026-07001.12M6
2026-06005.29M7
2026-0500664.13K4
2026-04001.04M5
2026-038.76M22.66M6
2026-0200646.90K4
2026-010011.05M9
2025-120000
2025-110060.07M7

Institutional holders

Manager% owned
Catalys Pacific, LLC8.82%
RA CAPITAL MANAGEMENT, L.P.8.73%
BlackRock, Inc.6.68%
Samsara BioCapital, LLC6.66%
FMR LLC5.33%
STATE STREET CORP4.70%
DEERFIELD MANAGEMENT COMPANY, L.P.4.49%
VANGUARD CAPITAL MANAGEMENT LLC3.13%
Laurion Capital Management LP2.81%
PRICE T ROWE ASSOCIATES INC /MD/2.57%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.20%
VANGUARD HEALTH CARE FUND2.25%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.23%
SMALLCAP World Fund Inc1.87%
iShares Russell 2000 ETF1.70%
Select Health Care Portfolio1.33%
T. Rowe Price New Horizons Fund, Inc.0.94%
Small Cap Growth Fund0.90%
VANGUARD EXTENDED MARKET INDEX FUND0.83%
Strategic Advisers Fidelity U.S. Total Stock Fund0.71%

OakChart. MLYS. Cached 15 minutes.